乳腺癌是女性最常见的恶性肿瘤,严重威胁女性的健康。由于医疗水平的发展,乳腺癌患者生存率的提高,双侧乳腺癌越来越受到重视。原发双侧乳腺癌（bilateral primary breast cancer,BPBC）指两侧乳房同时或先后发生独立的原发性乳腺癌。...乳腺癌是女性最常见的恶性肿瘤,严重威胁女性的健康。由于医疗水平的发展,乳腺癌患者生存率的提高,双侧乳腺癌越来越受到重视。原发双侧乳腺癌（bilateral primary breast cancer,BPBC）指两侧乳房同时或先后发生独立的原发性乳腺癌。根据其发病间隔时间的长短可分为同时性和异时性两种。同时性是指发现两侧乳腺癌的时间在半年以内,异时性是指其间隔时间在半年以上,间隔时间最长者可达二十几年。展开更多
乳腺癌是全球范围内女性最常见的恶性肿瘤，并且其发病率还在以每年2％的速度递增，且呈年轻化趋势。三阴乳腺癌是指雌激素受体（E R ）、孕激素受体（PR）及人表皮生长因子受体（Her-2）均为阴性的乳腺癌，约占乳腺癌的10％～17％。这...乳腺癌是全球范围内女性最常见的恶性肿瘤，并且其发病率还在以每年2％的速度递增，且呈年轻化趋势。三阴乳腺癌是指雌激素受体（E R ）、孕激素受体（PR）及人表皮生长因子受体（Her-2）均为阴性的乳腺癌，约占乳腺癌的10％～17％。这一类乳腺癌具有高度侵袭性，患者复发率高，5年生存率低，对内分泌治疗不敏感。本研究利用免疫组织化学法对128例三阴乳腺癌及168例非三阴乳腺癌组织中 P53及Ki67的表达进行比较，现报告如下。展开更多
含Jumonji C结构域蛋白6 (Jumonji C-domain containing protein 6, JMJD6)是Fe(Ⅱ)和α-酮戊二酸依赖性的加氧酶,它具有催化mRNA前体片段中蛋白赖氨酸残基羟化的作用。近年来,关于JMJD6在肿瘤的发生、发展及转移中的作用逐渐被揭示。JM...含Jumonji C结构域蛋白6 (Jumonji C-domain containing protein 6, JMJD6)是Fe(Ⅱ)和α-酮戊二酸依赖性的加氧酶,它具有催化mRNA前体片段中蛋白赖氨酸残基羟化的作用。近年来,关于JMJD6在肿瘤的发生、发展及转移中的作用逐渐被揭示。JMJD6不仅能通过其酶活性影响肿瘤细胞的表观遗传状态,还能通过与其他分子如核受体、转录因子等互作,调节肿瘤相关基因的表达。研究表明,JMJD6与多种肿瘤类型如乳腺癌、肺癌和前列腺癌等的发生密切相关。此外,JMJD6的活性与肿瘤患者的预后及药物敏感性相关,使其成为潜在的治疗靶点。目前,针对JMJD6的临床研究正在探索其作为生物标志物及治疗靶点的潜力,例如在抗肿瘤药物开发中的应用。本文旨在综述JMJD6的调控机制和临床研究进展,为未来的研究方向及临床应用提供理论基础。Jumonji C-domain containing protein 6 (JMJD6) is a Fe(II) and α-ketoglutarate-dependent dioxygenase that catalyzes the hydroxylation of lysine residues in precursor mRNA fragments. In recent years, the role of JMJD6 in tumorigenesis, development, and metastasis has been gradually elucidated. JMJD6 not only influences the epigenetic state of tumor cells through its enzymatic activity, but also regulates the expression of tumor-related genes by interacting with other molecules, such as nuclear receptors and transcription factors. Studies have shown that JMJD6 is closely associated with the occurrence of various types of tumors, such as breast cancer, lung cancer, and prostate cancer. Furthermore, the activity of JMJD6 is related to the prognosis and drug sensitivity of cancer patients, making it a potential therapeutic target. Currently, clinical studies on JMJD6 are exploring its potential as a biomarker and therapeutic target, for example, in the application of the development of anti-tumor drugs. This paper aims to review the regulatory mechanisms and clinical research progress of JMJD6, providing a theoretical basis for future research directions and clinical applications.展开更多
文摘乳腺癌是女性最常见的恶性肿瘤,严重威胁女性的健康。由于医疗水平的发展,乳腺癌患者生存率的提高,双侧乳腺癌越来越受到重视。原发双侧乳腺癌（bilateral primary breast cancer,BPBC）指两侧乳房同时或先后发生独立的原发性乳腺癌。根据其发病间隔时间的长短可分为同时性和异时性两种。同时性是指发现两侧乳腺癌的时间在半年以内,异时性是指其间隔时间在半年以上,间隔时间最长者可达二十几年。
文摘乳腺癌是全球范围内女性最常见的恶性肿瘤，并且其发病率还在以每年2％的速度递增，且呈年轻化趋势。三阴乳腺癌是指雌激素受体（E R ）、孕激素受体（PR）及人表皮生长因子受体（Her-2）均为阴性的乳腺癌，约占乳腺癌的10％～17％。这一类乳腺癌具有高度侵袭性，患者复发率高，5年生存率低，对内分泌治疗不敏感。本研究利用免疫组织化学法对128例三阴乳腺癌及168例非三阴乳腺癌组织中 P53及Ki67的表达进行比较，现报告如下。
文摘含Jumonji C结构域蛋白6 (Jumonji C-domain containing protein 6, JMJD6)是Fe(Ⅱ)和α-酮戊二酸依赖性的加氧酶,它具有催化mRNA前体片段中蛋白赖氨酸残基羟化的作用。近年来,关于JMJD6在肿瘤的发生、发展及转移中的作用逐渐被揭示。JMJD6不仅能通过其酶活性影响肿瘤细胞的表观遗传状态,还能通过与其他分子如核受体、转录因子等互作,调节肿瘤相关基因的表达。研究表明,JMJD6与多种肿瘤类型如乳腺癌、肺癌和前列腺癌等的发生密切相关。此外,JMJD6的活性与肿瘤患者的预后及药物敏感性相关,使其成为潜在的治疗靶点。目前,针对JMJD6的临床研究正在探索其作为生物标志物及治疗靶点的潜力,例如在抗肿瘤药物开发中的应用。本文旨在综述JMJD6的调控机制和临床研究进展,为未来的研究方向及临床应用提供理论基础。Jumonji C-domain containing protein 6 (JMJD6) is a Fe(II) and α-ketoglutarate-dependent dioxygenase that catalyzes the hydroxylation of lysine residues in precursor mRNA fragments. In recent years, the role of JMJD6 in tumorigenesis, development, and metastasis has been gradually elucidated. JMJD6 not only influences the epigenetic state of tumor cells through its enzymatic activity, but also regulates the expression of tumor-related genes by interacting with other molecules, such as nuclear receptors and transcription factors. Studies have shown that JMJD6 is closely associated with the occurrence of various types of tumors, such as breast cancer, lung cancer, and prostate cancer. Furthermore, the activity of JMJD6 is related to the prognosis and drug sensitivity of cancer patients, making it a potential therapeutic target. Currently, clinical studies on JMJD6 are exploring its potential as a biomarker and therapeutic target, for example, in the application of the development of anti-tumor drugs. This paper aims to review the regulatory mechanisms and clinical research progress of JMJD6, providing a theoretical basis for future research directions and clinical applications.
